

Gennari Luigi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/877199/gennari-luigi-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

160
papers

5,122
citations

42
h-index

65
g-index

171
ext. papers

5,780
ext. citations

5.3
avg. IF

5.28
L-index

#	Paper	IF	Citations
160	Osteoporosis in Men 2022 , 273-284		
159	Optimization of a Monobromobimane (MBB) Derivatization and RP-HPLC-FLD Detection Method for Sulfur Species Measurement in Human Serum after Sulfur Inhalation Treatment. <i>Antioxidants</i> , 2022 , 11, 939	7.1	2
158	Vitamin D Status and SARS-CoV-2 Infection and COVID-19 Clinical Outcomes.. <i>Frontiers in Public Health</i> , 2021 , 9, 736665	6	18
157	Vitamin D and COVID-19 severity and related mortality: a prospective study in Italy. <i>BMC Infectious Diseases</i> , 2021 , 21, 566	4	28
156	Case Report: An Unusual Case of Acute Lower Limb Ischemia as Precursor of the Asherson's Syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 727276	5.4	1
155	Cardiovascular complications of mild autonomous cortisol secretion. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2021 , 35, 101494	6.5	1
154	Selenium: A Trace Element for a Healthy Skeleton - A Narrative Review. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021 , 21, 577-585	2.2	4
153	Pulmonary Congestion Assessment in Heart Failure: Traditional and New Tools. <i>Diagnostics</i> , 2021 , 11,	3.8	4
152	Infection by CagA-Positive Helicobacter pylori Strains and Bone Fragility: A Prospective Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 80-89	6.3	2
151	Energy Metabolism and Ketogenic Diets: What about the Skeletal Health? A Narrative Review and a Prospective Vision for Planning Clinical Trials on this Issue. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
150	Hidden hypercortisolism: a too frequently neglected clinical condition. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 1581-1596	5.2	2
149	Effects of Bisphosphonate Treatment on Circulating Lipid and Glucose Levels in Patients with Metabolic Bone Disorders. <i>Calcified Tissue International</i> , 2021 , 108, 757-763	3.9	1
148	Management of bone fragility in type 2 diabetes: Perspective from an interdisciplinary expert panel. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 2210-2233	4.5	2
147	When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis. <i>Endocrine Practice</i> , 2021 , 27, 1216-1224	3.2	1
146	Management of Osteoporosis in Men: A Narrative Review.. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
145	Pathophysiology and Management of Type 2 Diabetes Mellitus Bone Fragility. <i>Journal of Diabetes Research</i> , 2020 , 2020, 7608964	3.9	25
144	Mutation of PFN1 Gene in an Early Onset, Polyostotic Paget-like Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	10

143	Characteristics of Early Paget's Disease in SQSTM1 Mutation Carriers: Baseline Analysis of the ZiPP Study Cohort. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 1246-1252	6.3	4
142	Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis. <i>Expert Review of Endocrinology and Metabolism</i> , 2020 , 15, 283-298	4.1	9
141	Emerging therapeutic targets for osteoporosis. <i>Expert Opinion on Therapeutic Targets</i> , 2020 , 24, 115-130.6.4		8
140	Prediction of hypertension, diabetes and fractures in eucortisolemic women by measuring parameters of cortisol milieu. <i>Endocrine</i> , 2020 , 68, 411-419	4	7
139	Treatment options for glucocorticoid-induced osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 721-732	4	13
138	Preventive Role of Vitamin D Supplementation for Acute Phase Reaction after Bisphosphonate Infusion in Paget's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	7
137	Increased Prevalence of Nephrolithiasis and Hyperoxaluria in Paget Disease of Bone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	2
136	Response to Letter to the Editor: "Methodological Issues Regarding Cortisol Secretion, Sensitivity, and Activity are Associated With Hypertension in Postmenopausal Eucortisolemic Women". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	1
135	Cortisol Secretion, Sensitivity, and Activity Are Associated With Hypertension in Postmenopausal Eucortisolemic Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 4441-4448	5.6	14
134	Paget's Disease of Bone. <i>Calcified Tissue International</i> , 2019 , 104, 483-500	3.9	32
133	Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 805-811	4	9
132	Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 579-604	6.3	51
131	Vitamin D Status in Paget Disease of Bone and Efficacy-Safety Profile of Cholecalciferol Treatment in Pagetic Patients with Hypovitaminosis D. <i>Calcified Tissue International</i> , 2019 , 105, 412-422	3.9	5
130	Clinical Guidelines on Paget's Disease of Bone. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 2327-2332.3		23
129	DIAGNOSIS OF ENDOCRINE DISEASE: Evaluation of bone fragility in endocrine disorders. <i>European Journal of Endocrinology</i> , 2019 ,	6.5	21
128	Zoledronate in the prevention of Paget's (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent -mediated Paget's disease of bone. <i>BMJ Open</i> , 2019 , 9, e030689	3	8
127	Falls, fractures and vitamin D: a never-ending story?. <i>Nature Reviews Rheumatology</i> , 2019 , 15, 6-8	8.1	4
126	New and developing pharmacotherapy for osteoporosis in men. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 253-264	4	15

125	Interleukin-6 trans-signaling and pathological low back pain in patients with Paget disease of bone. <i>Pain</i> , 2018 , 159, 1664-1673	8	3
124	Paget disease of bone: an update on epidemiology, pathogenesis and pharmacotherapy. <i>Expert Opinion on Orphan Drugs</i> , 2018 , 6, 485-496	1.1	9
123	Recent advances in models for screening potential osteoporosis drugs. <i>Expert Opinion on Drug Discovery</i> , 2018 , 13, 741-752	6.2	1
122	Identification of a novel locus on chromosome 2q13, which predisposes to clinical vertebral fractures independently of bone density. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 378-385	2.4	15
121	The Potential Role of miRNAs as New Biomarkers for Osteoporosis. <i>International Journal of Endocrinology</i> , 2018 , 2018, 2342860	2.7	22
120	Misdiagnosis of vertebral fractures on local radiographic readings of the multicentre POINT (Prevalence of Osteoporosis in INTERNAL medicine) study. <i>Bone</i> , 2017 , 101, 230-235	4.7	22
119	MicroRNAs in bone diseases. <i>Osteoporosis International</i> , 2017 , 28, 1191-1213	5.3	61
118	Activation of the Wnt Pathway by Small Peptides: Rational Design, Synthesis and Biological Evaluation. <i>ChemMedChem</i> , 2017 , 12, 2074-2085	3.7	8
117	Treatment needs and current options for postmenopausal osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1141-52	4	52
116	ZNF687 Mutations in Severe Paget Disease of Bone Associated with Giant Cell Tumor. <i>American Journal of Human Genetics</i> , 2016 , 98, 275-86	11	39
115	The impact of infarct size on regional and global left ventricular systolic function: a cardiac magnetic resonance imaging study. <i>International Journal of Cardiovascular Imaging</i> , 2015 , 31, 1037-44	2.5	13
114	Hypovitaminosis D and organ damage in patients with arterial hypertension: a multicenter double blind randomised controlled trial of cholecalciferol supplementation (HYPODD) : study design, clinical procedures and treatment protocol. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015 , 22, 125-132	2.9	3
113	Appropriate models for novel osteoporosis drug discovery and future perspectives. <i>Expert Opinion on Drug Discovery</i> , 2015 , 10, 1201-16	6.2	18
112	Clinical characteristics and evolution of giant cell tumor occurring in Paget's disease of bone. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 257-63	6.3	30
111	Letter to the Editor: The Endocrine Society Clinical Practice Guidelines on Paget's Disease: Many Recommendations Are Not Evidence Based. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, L45-6	5.6	4
110	Helicobacter pylori seroprevalence in patients with idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2014 , 43, 635-8	13.6	12
109	Undiagnosed vertebral fractures influence quality of life in postmenopausal women with reduced ultrasound parameters. <i>Clinical Orthopaedics and Related Research</i> , 2014 , 472, 2254-61	2.2	12
108	Paget disease of bone-associated UBA domain mutations of SQSTM1 exert distinct effects on protein structure and function. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014 , 1842, 992-1000	6.9	26

107	Paget's disease of bone: epidemiology, pathogenesis and pharmacotherapy. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 591-603	1.1	2
106	Idiopathic osteoporosis in men. <i>Current Osteoporosis Reports</i> , 2013 , 11, 286-98	5.4	15
105	Giant cell tumor occurring in familial Paget's disease of bone: report of clinical characteristics and linkage analysis of a large pedigree. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 341-50	6.3	15
104	Bisphosphonates target B cells to enhance humoral immune responses. <i>Cell Reports</i> , 2013 , 5, 323-30	10.6	25
103	Common susceptibility alleles and SQSTM1 mutations predict disease extent and severity in a multinational study of patients with Paget's disease. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 2338-46	6.3	43
102	Nuove acquisizioni patogenetiche e terapeutiche della malattia ossea di Paget. <i>L'Endocrinologo</i> , 2013 , 14, 120-127	0	
101	Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism. <i>Frontiers in Endocrinology</i> , 2013 , 4, 73	5.7	25
100	Endocrine actions of osteocalcin. <i>International Journal of Endocrinology</i> , 2013 , 2013, 846480	2.7	84
99	Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 1737-44	5.6	183
98	A nonsynonymous TNFRSF11A variation increases NFB activity and the severity of Paget's disease. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 443-52	6.3	31
97	Pharmacokinetic evaluation of toremifene and its clinical implications for the treatment of osteoporosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 505-13	5.5	5
96	Aromatase activity and bone loss. <i>Advances in Clinical Chemistry</i> , 2011 , 54, 129-64	5.8	13
95	Aromatase activity and bone loss in men. <i>Journal of Osteoporosis</i> , 2011 , 2011, 230671	2.8	19
94	Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. <i>Nature Genetics</i> , 2011 , 43, 685-9	36.3	134
93	The association of body composition and sex hormones with quantitative ultrasound parameters at the calcaneus and phalanges in elderly women. <i>Calcified Tissue International</i> , 2011 , 89, 456-63	3.9	13
92	Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 512-8	6.3	20
91	Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis. <i>Expert Opinion on Drug Discovery</i> , 2011 , 6, 205-17	6.2	4
90	Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. <i>Annals of Pharmacotherapy</i> , 2011 , 45, 499-509	2.9	9

89	The Genetics of Peak Bone Mass 2010 , 149-163		1
88	Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene. <i>Clinical Interventions in Aging</i> , 2010 , 5, 19-29	4	34
87	FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women. <i>European Journal of Endocrinology</i> , 2010 , 163, 165-72	6.5	76
86	Epidemiological, clinical, and genetic characteristics of Paget's disease of bone in a rural area of Calabria, Southern Italy. <i>Journal of Endocrinological Investigation</i> , 2010 , 33, 519-25	5.2	10
85	The relationship between plasma homocysteine levels and bone mineral density in post-menopausal women. <i>European Journal of Internal Medicine</i> , 2010 , 21, 301-5	3.9	34
84	Mechanisms of impaired bone strength in type 1 and 2 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010 , 20, 683-90	4.5	79
83	Pharmacogenomics of Osteoporosis. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2010 , 8, 77-94	2.5	5
82	SQSTM1 gene analysis and gene-environment interaction in Paget's disease of bone. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 1375-84	6.3	58
81	Lasofloxifene: Evidence of its therapeutic value in osteoporosis. <i>Core Evidence</i> , 2010 , 4, 113-29	4.9	8
80	Lasofloxifene: a new-generation SERM for the treatment of postmenopausal osteoporosis. <i>Expert Review of Obstetrics and Gynecology</i> , 2009 , 4, 607-617		
79	The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009 , 9, 1052-63	3.2	16
78	Ospemifene use in postmenopausal women. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 839-49	5.9	26
77	Update on the pharmacogenetics of the vitamin D receptor and osteoporosis. <i>Pharmacogenomics</i> , 2009 , 10, 417-33	2.6	18
76	Lasofloxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 2209-20	4	27
75	Glucocorticoid-induced osteoporosis: hope on the HORIZON. <i>Lancet, The</i> , 2009 , 373, 1225-6	4.0	14
74	Current options for the treatment of Paget's disease of the bone. <i>Open Access Rheumatology: Research and Reviews</i> , 2009 , 1, 107-120	2.4	10
73	Perspectives in the treatment and prevention of osteoporosis. <i>Drugs of Today</i> , 2009 , 45, 629	2.5	12
72	Malattia di Paget 2009 , 243-254		

71 Rachitismo e osteomalacia **2009**, 199-214

70 Perspectives in the treatment and prevention of osteoporosis. *Drugs of Today*, **2009**, 45, 629-47 2.5

69 Raloxifene in breast cancer prevention. *Expert Opinion on Drug Safety*, **2008**, 7, 259-70 4.1 25

68 The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels. *Thyroid*, **2008**, 18, 455-60 6.2 64

67 Does calcium supplementation reduce the risk of osteoporotic fracture and bone loss?. *Nature Clinical Practice Rheumatology*, **2008**, 4, 70-1 1

66 Estrogen Effects on Bone in the Male Skeleton **2008**, 1801-1818 1

65 Bazedoxifene for the prevention of postmenopausal osteoporosis. *Therapeutics and Clinical Risk Management*, **2008**, 4, 1229-42 2.9 23

64 The effects of zoledronic acid on serum lipids in multiple myeloma patients. *Calcified Tissue International*, **2008**, 82, 258-62 3.9 18

63 Vitamin D receptor gene polymorphisms predict acquired resistance to clodronate treatment in patients with Paget's disease of bone. *Calcified Tissue International*, **2008**, 83, 414-24 3.9 15

62 Osteoporosis in men: Pathophysiology and treatment. *Current Sexual Health Reports*, **2008**, 5, 83-89 1.2

61 Estrogen and fracture risk in men. *Journal of Bone and Mineral Research*, **2008**, 23, 1548-51 6.3 34

60 Steroid hormone receptor gene polymorphisms and osteoporosis: a pharmacogenomic review. *Expert Opinion on Pharmacotherapy*, **2007**, 8, 537-53 4 22

59 Osteoporosis in men. *Endocrinology and Metabolism Clinics of North America*, **2007**, 36, 399-419 5.5 74

58 Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone. *Journal of Bone and Mineral Research*, **2007**, 22, 1510-7 6.3 61

57 Osteoporosis in men: pathophysiology and treatment. *Current Osteoporosis Reports*, **2007**, 5, 22-8 5.4 5

56 Osteoporosis in men: pathophysiology and treatment. *Current Rheumatology Reports*, **2007**, 9, 71-7 4.9 8

55 Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. *Bone*, **2007**, 40, 457-63 4.7 62

54 Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. *Drugs and Aging*, **2007**, 24, 361-79 4.7 81

53	Estrogen in men: effects on bone accrual, maintenance and prevention of bone loss. <i>Expert Review of Endocrinology and Metabolism</i> , 2006 , 1, 281-295	4.1	5
52	Lasofloxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis. <i>Expert Opinion on Investigational Drugs</i> , 2006 , 15, 1091-103	5.9	42
51	Paget's disease of bone in Italy. <i>Journal of Bone and Mineral Research</i> , 2006 , 21 Suppl 2, P14-21	6.3	50
50	Evidence for increased clinical severity of familial and sporadic Paget's disease of bone in Campania, southern Italy. <i>Journal of Bone and Mineral Research</i> , 2006 , 21, 1828-35	6.3	51
49	Lasofloxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis. <i>Drugs of Today</i> , 2006 , 42, 355-67	2.5	26
48	Zoledronic Acid Early Increases Serum Osteoprotegerin in Early Stage Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 3588-3588	2.2	
47	Estrogen receptor gene polymorphisms and the genetics of osteoporosis: a HuGE review. <i>American Journal of Epidemiology</i> , 2005 , 161, 307-20	3.8	168
46	Left ventricular diastolic function improvement by carvedilol therapy in advanced heart failure. <i>Journal of Cardiovascular Pharmacology</i> , 2005 , 45, 563-8	3.1	24
45	Characteristics and familial aggregation of Paget's disease of bone in Italy. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 1356-64	6.3	57
44	Prevalence of Paget's disease of bone in Italy. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 1845-50	6.3	65
43	Relation of plasma brain natriuretic peptide levels in non-ST-elevation coronary disease and preserved systolic function to number of narrowed coronary arteries. <i>American Journal of Cardiology</i> , 2005 , 96, 1705-10	3	20
42	Quantitative ultrasound and dual-energy X-ray absorptiometry in the prediction of fragility fracture in men. <i>Osteoporosis International</i> , 2005 , 16, 963-8	5.3	74
41	Prevalence of Helicobacter pylori infection in male patients with osteoporosis and controls. <i>Digestive Diseases and Sciences</i> , 2005 , 50, 847-52	4	43
40	Oral ibandronic acid. <i>IDrugs: the Investigational Drugs Journal</i> , 2005 , 8, 155-69		
39	Lasofloxifene (Pfizer). <i>Current Opinion in Investigational Drugs</i> , 2005 , 6, 1067-78		10
38	Aromatase activity and bone homeostasis in men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 5898-907	5.6	142
37	A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2803-10	5.6	141
36	Left ventricular hypertrophy differences in male professional runners and in young patients suffering from mild hypertension. <i>Blood Pressure</i> , 2004 , 13, 14-9	1.7	1

35	Feasibility of quantitative ultrasound measurements on the humerus of newborn infants for the assessment of the skeletal status. <i>Osteoporosis International</i> , 2004 , 15, 541-6	5.3	26
34	Dual X-ray and laser absorptiometry of the calcaneus: comparison with quantitative ultrasound and dual-energy X-ray absorptiometry. <i>Journal of Clinical Densitometry</i> , 2004 , 7, 349-54	3.5	21
33	Vitamin D status and bone turnover in women with acute hip fracture. <i>Clinical Orthopaedics and Related Research</i> , 2004 , 208-13	2.2	48
32	Ospemifene Hormos. <i>Current Opinion in Investigational Drugs</i> , 2004 , 5, 448-55		11
31	Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. <i>Calcified Tissue International</i> , 2003 , 73, 133-9	3.9	73
30	Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 5327-33	5.6	203
29	Mild brachydactyly type A1 maps to chromosome 2q35-q36 and is caused by a novel IHH mutation in a three generation family. <i>Journal of Medical Genetics</i> , 2003 , 40, 132-5	5.8	21
28	PTH in the pathogenesis and treatment of glucocorticoid-induced osteoporosis. <i>Frontiers of Hormone Research</i> , 2002 , 30, 184-97	3.5	2
27	Heel ultrasonography in monitoring alendronate therapy: a four-year longitudinal study. <i>Osteoporosis International</i> , 2002 , 13, 415-21	5.3	43
26	Infection by CagA-positive <i>Helicobacter pylori</i> strains in patients with ischemic heart disease: prevalence and association with exercise-induced electrocardiographic abnormalities. <i>Digestive Diseases and Sciences</i> , 2002 , 47, 831-6	4	14
25	Association of polymorphisms of the estrogen receptor alpha gene with bone mineral density and fracture risk in women: a meta-analysis. <i>Journal of Bone and Mineral Research</i> , 2002 , 17, 2048-60	6.3	153
24	<i>Helicobacter pylori</i> infection and infertility. <i>European Journal of Gastroenterology and Hepatology</i> , 2002 , 14, 663-9	2.2	51
23	Genetics of osteoporosis: role of steroid hormone receptor gene polymorphisms. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2002 , 81, 1-24	5.1	72
22	Genetics of male osteoporosis. <i>Calcified Tissue International</i> , 2001 , 69, 200-4	3.9	34
21	Dual X-ray absorptiometry and bone ultrasonography in patients with Rett syndrome. <i>Calcified Tissue International</i> , 2001 , 69, 259-62	3.9	43
20	Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 2263-9	5.6	80
19	Genotype distribution of estrogen receptor-alpha gene polymorphisms in Italian women with surgical uterine leiomyomas. <i>Fertility and Sterility</i> , 2001 , 75, 567-70	4.8	33
18	Genetic markers of osteoarticular disorders: facts and hopes. <i>Arthritis Research</i> , 2001 , 3, 270-80		26

17	Effect of electromagnetic fields on bone mineral density and biochemical markers of bone turnover in osteoporosis: a single-blind, randomized pilot study. <i>Current Therapeutic Research</i> , 2001 , 62, 187-193	2.4	35
16	Usefulness of bone quantitative ultrasound in management of osteoporosis in men. <i>Journal of Clinical Densitometry</i> , 2001 , 4, 231-7	3.5	15
15	Absence of correlation between BMP-4 polymorphism and postmenopausal osteoporosis in Italian women. <i>Calcified Tissue International</i> , 2000 , 67, 93-4	3.9	9
14	Quantitative ultrasound and bone mineral density in patients with primary hyperparathyroidism before and after surgical treatment. <i>Osteoporosis International</i> , 2000 , 11, 255-60	5.3	37
13	Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor alpha gene and their relationship to bone mass variation in postmenopausal Italian women. <i>Human Molecular Genetics</i> , 2000 , 9, 2043-50	5.6	131
12	FokI polymorphism at translation initiation site of the vitamin D receptor gene predicts bone mineral density and vertebral fractures in postmenopausal Italian women. <i>Journal of Bone and Mineral Research</i> , 1999 , 14, 1379-86	6.3	77
11	Telomerase repeat amplification protocol (TRAP): A new molecular marker for parathyroid carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 1999 , 265, 252-5	3.4	21
10	Association of the estrogen receptor alpha gene polymorphisms with sporadic Alzheimer's disease. <i>Biochemical and Biophysical Research Communications</i> , 1999 , 265, 335-8	3.4	113
9	Age-related decline of bone mass and intestinal calcium absorption in normal males. <i>Calcified Tissue International</i> , 1998 , 63, 197-201	3.9	36
8	Allelic variants of human calcitonin receptor: distribution and association with bone mass in postmenopausal Italian women. <i>Biochemical and Biophysical Research Communications</i> , 1998 , 245, 622-6	3.4	44
7	Polymorphisms of the calcitonin receptor gene are associated with bone mineral density in postmenopausal Italian women. <i>Biochemical and Biophysical Research Communications</i> , 1998 , 248, 190-5	3.4	79
6	Vitamin D and estrogen receptor allelic variants in Italian postmenopausal women: evidence of multiple gene contribution to bone mineral density. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 939-44	5.6	154
5	The combined use of ultrasound and densitometry in the prediction of vertebral fracture. <i>British Journal of Radiology</i> , 1997 , 70, 691-6	3.4	49
4	Vitamin D receptor genotypes and intestinal calcium absorption in postmenopausal women. <i>Calcified Tissue International</i> , 1997 , 61, 460-3	3.9	85
3	Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study. <i>Clinical Endocrinology</i> , 1997 , 46, 55-61	3.4	22
2	Membrane binding sites and non-genomic effects of estrogen in cultured human pre-osteoclastic cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1996 , 59, 233-40	5.1	60
1	Molecular Genetics of Paget's Disease of Bone		2